
Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its hereditary angioedema (HAE) candidate. This milestone represents the first-ever global Phase 3 data for an in vivo CRISPR therapy, proving the technology is clinically viable.
Intellia Therapeutics stock has been a lucrative investment in 2026, currently up more than 50% versus the start of this year.